Incannex Healthcare Inc. Common Stock (IXHL)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham style investor, I look for durable earnings power and a margin of safety. Incannex is a clinical-stage biopharma with 12 employees and no marketed products; its value rests on IHL-42X and PSX-001 trials, not present cash flows. The filed numbers are stark: in fiscal FY2026, the year ended 2026-06-30, net loss was $19.3 million and diluted EPS was -$1.66; FY2025 net loss was $46.9 million on revenue of $86,000; FY2024 net loss was $18.5 million on revenue of $12,000. Trailing free cash flow was -$19.4 million, a FairStock calculation, giving a -53.2% FCF yield against the $36.5 million market cap at the 2026-10-13 close. The Piotroski F-Score is 2/9 and the Altman Z-Score is 2.30, both FairStock calculations, suggesting weak financial strength. The P/B of 0.53 means the shares trade below accounting book value, but with negative ROE of -47.80% and ROCE of -24.58% (FairStock calculations), book value is being consumed by losses. The beta of 2.83 and 52-week range of $2.49 to $14.91 show speculative volatility. There is no debt, which is a modest positive, but no revenue and no profits mean no moat I can underwrite. A Lynch category is none because the company lost money in each of the last four years. Until trial data and a path to cash flow appear, this is speculation, not a Graham-style value investment.

In plain English: Incannex Healthcare is a small drug developer testing medicines for sleep apnea and anxiety. It has almost no product sales and is losing money. The stock price looks low compared with its accounting value, but the business itself is unproven and risky.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer